Management of Immune Checkpoint Inhibitor-Related Rheumatological Toxicities
| Autor: | Ho Yin Chung, Pak Yui Fong, Charlene Cheuk Lam Lau, Christy Yik Ching Lau, Cheuk Yin Matthew Wong, Shing Chuen Chow, Benedict Tsz Hin Yan, Ha Ying Nip, Bernard Ming Hong Kwong, Athena Hoi Ting Lee |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
lcsh:Immunologic diseases. Allergy
medicine.medical_specialty Immune checkpoint inhibitors Inflammatory arthritis medicine.medical_treatment rheumatology immune checkpoint inhibitors 03 medical and health sciences 0302 clinical medicine Internal medicine Programmed cell death 1 medicine Cytotoxic T cell inflammatory arthritis 030203 arthritis & rheumatology biology business.industry Cancer Immunotherapy medicine.disease Rheumatology 030220 oncology & carcinogenesis iraes biology.protein Cancer research immune-related adverse events immunotherapy business lcsh:RC581-607 |
| Zdroj: | Journal of Clinical Rheumatology and Immunology, Vol 20, Iss 1, Pp 25-34 (2020) |
| ISSN: | 2661-3425 2661-3417 |
| Popis: | Immune checkpoint inhibitors (ICIs) have forged a new direction for the treatment of cancer. However, ICIs – programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors – are also known to cause immune-related adverse events (irAEs). Rheumatological adverse events are uncommon and often low grade, but flares of underlying rheumatological diseases may be triggered. Guidelines are available for the effective management of the rheumatological adverse events that more frequently arise from the use of ICIs, such as inflammatory arthritis, inflammatory myopathies, Sjogren syndrome, scleroderma, and polymyalgia rheumatica and eosinophilic fasciitis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|